TrialCancer communications (London, England)2024

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.

Jing Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.